Medicalgorithmics, a Warsaw Stock Exchange-listed developer of advanced cardiology technologies, is taking an important step toward expanding its therapeutic capabilities in cardiac surgery. The company has signed a letter of intent with the Prof. Zbigniew Religa Foundation for Cardiac Surgery Development in Zabrze and Biofund Capital Management. The parties are now negotiating the terms of cooperation on the development of a proprietary surgical robot.
The project aims to create a minimally invasive robotic system designed to support physicians in procedures for the treatment of structural heart defects. Once introduced to the market, the system could become a major milestone for Medicalgorithmics in building a full diagnostic and therapeutic model — from advanced analysis and detection of heart diseases and defects to technologies supporting their precise and effective treatment.
“Potential work on an innovative cardiac surgery robot would be a perfect complement to Medicalgorithmics’ project portfolio. We already fully support the diagnosis of cardiac arrhythmias through software and devices for ECG analysis, as well as non-invasive diagnostics of coronary artery disease through VCAST technology. Our latest project would use diagnostic technologies we have already developed, such as automatic segmentation and analysis of heart structures based on computed tomography, within the VCAST project, in real patient treatment. This will be possible by combining our know-how in algorithms, software and electronic systems with the Foundation’s extensive expertise in heart valves, cardiac robotics and cardiac surgery,” said Dr Kris Siemionow, CEO of Medicalgorithmics.
Following the signing of the letter of intent, Medicalgorithmics, Biofund Capital Management and the Prof. Zbigniew Religa Foundation for Cardiac Surgery Development in Zabrze are starting negotiations. Their goal is to establish cooperation on the development and market launch of a minimally invasive robotic platform for structural interventions in cardiology. The platform is expected to combine advanced CT-based anatomical analysis and planning software, surgical and mechatronic systems, and solutions designed to optimize clinical workflow.
According to Medicalgorithmics, Biofund is expected to play an important role in the negotiated agreement, not only by supporting the project financially and strategically, but also by contributing know-how and intellectual property developed in this area.
“Biofund already has companies in its portfolio that combine cardiac surgery robotics with catheterization technology and next-generation implants, including Capstan Medical, Versa Medical and Kardibot,” Dr Siemionow said.
Biofund Capital Management’s portfolio includes several cardiology and cardiac surgery projects that have attracted strong interest from investors and the medical community. Capstan Medical, a surgical robotics project, secured USD 110 million in financing in December 2024. Another cardiology-related project, Versa Medical, raised USD 27.3 million in July 2025.
Medicalgorithmics also points to the strategic scientific contribution of the Prof. Zbigniew Religa Foundation for Cardiac Surgery Development to the potential joint project.
“We are very proud to begin talks with the Foundation for Cardiac Surgery Development. Cooperation with a leading European cardiology institution is, firstly, a major distinction for Medicalgorithmics and, secondly, an important confirmation that we have chosen the right direction. It is also close to a guarantee that the solution delivered will offer the highest therapeutic quality,” added Dr Siemionow.
Dr hab. n. med. Zbigniew Nawrat, Creative Director of the Foundation for Cardiac Surgery Development, emphasized that the project is aligned with the Foundation’s mission.
“Our goal is to continuously improve the quality of patient treatment, which is why we are engaging in a project with real potential to achieve this. A minimally invasive cardiac surgery robot that we can design together has a chance to significantly improve the performance of operations. I believe that our joint robot will support cardiac surgeons in their daily work of saving patients’ lives,” said Dr Nawrat.
The Prof. Zbigniew Religa Foundation for Cardiac Surgery Development in Zabrze is one of Poland’s most important research and scientific institutions in the field of cardiac surgery. Since 1991, it has continued the vision of its patron by developing and introducing modern life-saving technologies into clinical practice.
The Foundation focuses on the development and implementation of heart support systems, including Polish artificial heart prostheses from the ReligaHeart family, as well as medical robotics and innovative solutions in bioengineering and biotechnology. By combining scientific research with clinical medicine, the Foundation supports progress in Polish cardiac surgery, trains medical specialists and helps set standards for modern heart failure treatment on an international scale.
